Clinical Features and Outcome of the Guillain-Barre Syndrome: A Single-Center 11-Year Experience

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Jul 21

PMID 35860488

Authors

Federica Ginanneschi

Fabio Giannini

Francesco Sicurelli

Carla Battisti

Giorgio Capoccitti

Sabina Bartalini

Andrea Mignarri

Nila Volpi

David Cioncoloni

Laura Franci

Nicola De Stefano

Alessandro Rossi

Affiliations

Soon will be listed here.

Abstract

Background: Clinical presentation, electrophysiological subtype, and outcome of the Guillain-Barre' Syndrome (GBS) may differ between patients from different geographical regions. This study aims to assess clinical-neurophysiological features of an adult, Italian GBS cohort over 11 years.

Methods: Retrospective (from 1 January 2011 to 31 December 2021) analysis was carried out on patients admitted to the Siena University Hospital who fulfilled the GBS diagnostic criteria. Demographic data, clinical characteristics, treatment, need of mechanical ventilation (MV), laboratory and electrophysiological tests, preceding infections/vaccination/other conditions, and comorbidities were collected for each patient.

Results: A total of 84 patients (51 men, median age of 61 years), were identified. GBS subtype was classified as acute inflammatory demyelinating polyneuropathy (AIDP) in the 66.6% of patients, acute motor/sensory axonal neuropathy (AMAN/AMSAN) in 20.2%, and the Miller Fisher syndrome in 5 (5.9%). Flu syndrome and gastrointestinal infection were the most common preceding conditions. In total, five (5.9%) subjects had concomitant cytomegalovirus (CMV) infection. Cranial nerve involvement occurred in 34.5% of subjects. Differences between the axonal and AIDP forms of GBS concerned the presence of anti-ganglioside antibodies. In total, seven (8.33%) patients required MV.

Discussion: The epidemiological and clinical characteristics of GBS in different countries are constantly evolving, especially in relation to environmental changes. This study provides updated clinical-epidemiological information in an Italian cohort.

Citing Articles

Predictors of respiratory failure in Guillain-Barré syndrome: a 22 year cohort study from a single Italian centre.

Galassi G, Mazzoli M, Ariatti A, Bedin R, Marzullo D, Bastia E Eur J Neurol. 2023; 31(1):e16090.

PMID: 37823704 PMC: 11235807. DOI: 10.1111/ene.16090.

COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.

Malekpour M, Khanmohammadi S, Meybodi M, Shekouh D, Rahmanian M, Kardeh S Immun Inflamm Dis. 2023; 11(5):e875.

PMID: 37249286 PMC: 10187022. DOI: 10.1002/iid3.875.

Triggers of Guillain-Barré Syndrome: Predominates.

Finsterer J Int J Mol Sci. 2022; 23(22).

PMID: 36430700 PMC: 9696744. DOI: 10.3390/ijms232214222.

Guillain-Barré Syndrome in Northern China: A Retrospective Analysis of 294 Patients from 2015 to 2020.

Zhai Q, Guo C, Xue F, Qiang J, Li C, Guo L J Clin Med. 2022; 11(21).

PMID: 36362550 PMC: 9658830. DOI: 10.3390/jcm11216323.

References

Green C, Baker T, Subramaniam A . Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust. 2018; 208(4):181-188. DOI: 10.5694/mja17.00552. View

Benedetti M, Pugliatti M, DAlessandro R, Beghi E, Chio A, Logroscino G . A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. Neuroepidemiology. 2015; 45(2):90-9. DOI: 10.1159/000438752. View

McGrogan A, Madle G, Seaman H, de Vries C . The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2008; 32(2):150-63. DOI: 10.1159/000184748. View

Visser L, van der Meche F, Meulstee J, Rothbarth P, Jacobs B, Schmitz P . Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology. 1996; 47(3):668-73. DOI: 10.1212/wnl.47.3.668. View

Hughes R, Perkin G, PIERCE J . Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2(8093):750-3. DOI: 10.1016/s0140-6736(78)92644-2. View

Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn P, Jacobs B . Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2013; 137(Pt 1):33-43. DOI: 10.1093/brain/awt285. View

Bocci S, Giannini F, Volpi N, Rossi A, Ginanneschi F . Multifocal motor neuropathy occurring after acute motor axonal neuropathy: two stages of the same disease?. Neurol Sci. 2021; 43(2):1463-1465. DOI: 10.1007/s10072-021-05725-x. View

Filosto M, Piccinelli S, Gazzina S, Foresti C, Frigeni B, Servalli M . Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2020; 92(7):751-756. DOI: 10.1136/jnnp-2020-324837. View

Ang C, Jacobs B, Brandenburg A, Laman J, van der Meche F, Osterhaus A . Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology. 2000; 54(7):1453-8. DOI: 10.1212/wnl.54.7.1453. View

10.

Uncini A, Kuwabara S . Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012; 123(8):1487-95. DOI: 10.1016/j.clinph.2012.01.025. View

11.

Yuki N . Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis. 2002; 1(1):29-37. DOI: 10.1016/S1473-3099(01)00019-6. View

12.

Yuki N, Hartung H . Guillain-Barré syndrome. N Engl J Med. 2012; 366(24):2294-304. DOI: 10.1056/NEJMra1114525. View

13.

Chroni E, Papapetropoulos S, Gioldasis G, Ellul J, Diamadopoulos N, Papapetropoulos T . Guillain-Barré syndrome in Greece: seasonality and other clinico-epidemiological features. Eur J Neurol. 2004; 11(6):383-8. DOI: 10.1111/j.1468-1331.2004.00799.x. View

14.

Jacobs B, Rothbarth P, van der Meche F, Herbrink P, Schmitz P, de Klerk M . The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998; 51(4):1110-5. DOI: 10.1212/wnl.51.4.1110. View

15.

Leung J, Sejvar J, Soares J, Lanzieri T . Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009-2015. Neurol Sci. 2019; 41(4):885-891. PMC: 7501740. DOI: 10.1007/s10072-019-04156-z. View

16.

Luigetti M, Servidei S, Modoni A, Rossini P, Sabatelli M, Lo Monaco M . Admission neurophysiological abnormalities in Guillain-Barré syndrome: A single-center experience. Clin Neurol Neurosurg. 2015; 135:6-10. DOI: 10.1016/j.clineuro.2015.05.001. View

17.

Hughes R, Hadden R, Gregson N, Smith K . Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 2000; 100(1-2):74-97. DOI: 10.1016/s0165-5728(99)00195-2. View

18.

van den Berg B, Storm E, Garssen M, Blomkwist-Markens P, Jacobs B . Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. J Neurol Neurosurg Psychiatry. 2018; 89(9):949-954. DOI: 10.1136/jnnp-2018-317968. View

19.

Agosti E, Giorgianni A, DAmore F, Vinacci G, Balbi S, Locatelli D . Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci. 2020; 42(2):607-612. PMC: 7343406. DOI: 10.1007/s10072-020-04553-9. View

20.

Kobori S, Kubo T, Otani M, Muramatsu K, Fujino Y, Adachi H . Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome. J Epidemiol. 2017; 27(7):311-316. PMC: 5498408. DOI: 10.1016/j.je.2016.07.003. View